Commonwealth Bank of Australia’s Rigel Pharmaceuticals RIGL Stock Holding History

Commonwealth Bank of Australia’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-3,020	Closed	-$117K	–	984
2014 Q1	$117K	Buy	3,020 +90	+3%	+$3.21K	﹤0.01%	1225
2013 Q4	$84K	Hold	2,930	–	–	﹤0.01%	1207
2013 Q3	$105K	Sell	2,930 -9,100	-76%	-$332K	﹤0.01%	1185
2013 Q2	$402K	Buy	+12,030	New	+$545K	﹤0.01%	1001

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Commonwealth Bank of Australia's RIGL Position: Q2 2014 in Review

Commonwealth Bank of Australia sold out of Rigel Pharmaceuticals (RIGL) in Q2 2014, closing a stake of 3,020 shares — an estimated $117K sold.

Commonwealth Bank of Australia first reported a position in RIGL in Q2 2013 and held it in 4 quarters. The position peaked at $402K in Q2 2013. 103 funds tracked by Wall St. Rank hold RIGL as of Q2 2014.

Commonwealth Bank of Australia reported no remaining Rigel Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Commonwealth Bank of Australia sold 3,020 Rigel Pharmaceuticals shares in Q2 2014, an estimated $117K.
Commonwealth Bank of Australia first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Commonwealth Bank of Australia's Rigel Pharmaceuticals position peaked at $402K in Q2 2013.
103 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2014.

Based on Commonwealth Bank of Australia's 13F filing for Q2 2014, filed 11 Aug 2014.